Executive order sets drug price targets for most-favored-nations

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

On May 12, President Trump signed an executive order directing the administration to communicate most-favored-nation drug price targets to pharmaceutical manufacturers for sales in the United States.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Jacquelyn Cobb
Associate Editor
Table of Contents

YOU MAY BE INTERESTED IN

The Centers for Medicare & Medicaid Services issued the 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule, which aims to shorten care delays and improve transparency within federal health insurance programs by establishing electronic prior authorization, or ePA, requirements for covered prescription drugs and expedite federal response deadlines to ensure patients receive life-critical medications without administrative delay.
Jacquelyn Cobb
Associate Editor

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login